Millennium Management LLC Buys 135,246 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Millennium Management LLC boosted its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 138.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 233,132 shares of the company's stock after buying an additional 135,246 shares during the period. Millennium Management LLC owned 0.44% of Zevra Therapeutics worth $1,944,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its holdings in shares of Zevra Therapeutics by 51.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company's stock valued at $172,000 after purchasing an additional 6,966 shares during the last quarter. BNP Paribas Financial Markets bought a new position in shares of Zevra Therapeutics during the 4th quarter valued at about $53,000. Deutsche Bank AG boosted its holdings in shares of Zevra Therapeutics by 25.4% during the 4th quarter. Deutsche Bank AG now owns 50,906 shares of the company's stock valued at $425,000 after purchasing an additional 10,306 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Zevra Therapeutics by 50.5% during the 4th quarter. JPMorgan Chase & Co. now owns 27,490 shares of the company's stock valued at $229,000 after purchasing an additional 9,225 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Zevra Therapeutics during the 4th quarter valued at about $224,000. Hedge funds and other institutional investors own 35.03% of the company's stock.

Zevra Therapeutics Trading Up 4.9%

NASDAQ ZVRA traded up $0.43 during trading on Friday, hitting $9.26. The stock had a trading volume of 1,339,820 shares, compared to its average volume of 657,183. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The stock has a market capitalization of $506.34 million, a price-to-earnings ratio of -4.70 and a beta of 2.01. Zevra Therapeutics, Inc. has a one year low of $4.20 and a one year high of $9.76. The stock has a 50 day simple moving average of $7.76 and a 200 day simple moving average of $8.08.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.15. The business had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same quarter last year, the firm earned ($0.40) earnings per share. Sell-side analysts predict that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have commented on ZVRA shares. Wall Street Zen raised shares of Zevra Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Zevra Therapeutics in a report on Thursday, March 13th. Guggenheim increased their price target on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, March 13th. Canaccord Genuity Group increased their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, March 13th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price target on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $22.29.

Insiders Place Their Bets

In other news, Director John B. Bode acquired 10,000 shares of the firm's stock in a transaction on Wednesday, March 19th. The stock was acquired at an average price of $7.96 per share, with a total value of $79,600.00. Following the completion of the purchase, the director now directly owns 40,000 shares in the company, valued at approximately $318,400. This trade represents a 33.33% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 2.40% of the stock is owned by insiders.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.